-
公开(公告)号：US20240360418A1
公开(公告)日：2024-10-31
申请号：US18630991
申请日：2024-04-09
申请人： SDF BioPharma Inc.
发明人： Gerald SWISS , David KIEWLICH
IPC分类号： C12N5/071 , A61K35/17 , A61K35/39 , A61P3/10 , C07K14/52 , C12N5/0781 , C12N5/0783
CPC分类号： C12N5/0676 , A61K35/17 , A61K35/39 , A61P3/10 , C07K14/522 , C12N5/0635 , C12N5/0638 , C12N5/0646 , C12N5/0686 , C12N2501/998 , C12N2502/11 , C12N2502/99 , C12N2510/00
摘要： Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
-
2.发明公开公开(公告)号：US20240317889A1
公开(公告)日：2024-09-26
申请号：US18036156
申请日：2021-11-09
发明人： Zeling Cai , Yi Chen
IPC分类号： C07K16/32 , A61K35/17 , A61K38/00 , A61K47/65 , A61P35/00 , C07K14/52 , C12N5/071 , C12N15/85
CPC分类号： C07K16/32 , A61K35/17 , A61K47/65 , A61P35/00 , C07K14/523 , C12N5/0682 , C12N15/85 , A61K38/00 , C07K2319/00 , C12N2800/107
摘要： Provided are an anti-Her-2 antibody-chemokine fusion protein, a preparation method therefor and an application thereof. Specifically, provided is a fusion protein, the fusion protein comprising an anti-Her-2 antibody or an active fragment thereof and a chemokine. The fusion protein of the present invention enhances the lethality of eosinophils in a tumor microenvironment by means of CCL11-mediated chemotaxis while being able to recognize tumors abnormally expressing Her-2 and inhibiting the growth thereof, further enhancing the lethality thereof toward Her-2+ tumors.
-
公开(公告)号：US20240285775A1
公开(公告)日：2024-08-29
申请号：US18527005
申请日：2023-12-01
申请人： Yale University
发明人： Elias QUIJANO , Peter GLAZER
IPC分类号： A61K47/54 , A61K39/00 , A61K47/68 , A61K48/00 , A61P35/00 , C07K14/47 , C07K14/52 , C07K16/44 , C12N15/11 , C12N15/113 , C12N15/87
CPC分类号： A61K47/549 , A61K47/6807 , A61K47/6851 , A61K48/0025 , A61K48/005 , A61P35/00 , C07K14/4747 , C07K14/52 , C07K16/44 , C12N15/111 , C12N15/113 , C12N15/1135 , C12N15/87 , A61K2039/505 , A61K48/00 , C07K2317/24 , C07K2317/31 , C07K2317/565 , C07K2317/622 , C07K2317/77 , C07K2319/33 , C12N2310/11 , C12N2310/14 , C12N2310/3181 , C12N2310/3513 , C12N2320/32
摘要： Compositions and methods of use thereof for delivering nucleic acid cargo into cells are provided. The compositions typically include (a) a 3E10 monoclonal antibody or an antigen binding, cell-penetrating fragment thereof; a monovalent, divalent, or multivalent single chain variable fragment (scFv); or a diabody; or humanized form or variant thereof, and (b) a nucleic acid cargo including, for example, a nucleic acid encoding a polypeptide, a functional nucleic acid, a nucleic acid encoding a functional nucleic acid, or a combination thereof. Elements (a) and (b) are typically non-covalently linked to form a complex.
-
公开(公告)号：US12016881B2
公开(公告)日：2024-06-25
申请号：US17396792
申请日：2021-08-09
申请人： NEW YORK UNIVERSITY
发明人： Dafna Bar-Sagi , Jane Cullis , Craig Ramirez
IPC分类号： A61K38/38 , A61K31/337 , A61K35/15 , A61K38/00 , A61K38/18 , A61K38/19 , A61K38/20 , A61P35/00 , C07K14/52 , C07K14/53 , C07K14/54 , C07K14/76 , C07K14/765 , C12N5/0786
CPC分类号： A61K35/15 , A61K31/337 , A61K38/00 , A61K38/18 , A61K38/19 , A61K38/193 , A61K38/20 , A61K38/2006 , A61K38/2026 , A61K38/2066 , A61K38/385 , A61P35/00 , C07K14/52 , C07K14/53 , C07K14/54 , C07K14/5406 , C07K14/5428 , C07K14/76 , C07K14/765 , C12N5/0645 , C12N2501/22 , C12N2501/2301 , C12N2501/2304 , C12N2501/2306 , C12N2501/231 , C12N2501/2333 , C12N2501/24 , C12N2501/25
摘要： The present invention is directed to methods of inducing a phenotypic change in a population of monocytes and/or macrophages. The method includes administering to the population of monocytes and/or macrophages, a macrophage stimulating agent coupled to a carrier molecule, wherein the carrier molecule facilitates macropinocytic uptake of the agent by monocytes and macrophages in the population and is defective in neonatal Fc receptor binding, wherein the administering induces a phenotypic change in the monocytes and macrophages in the population.
-
5.发明公开公开(公告)号：US20240191252A1
公开(公告)日：2024-06-13
申请号：US18286103
申请日：2022-04-07
发明人： Xiaoqing CHEN , Yuanyuan LIU , Ziwen LIU , Tianyi DENG , Grace Guoying ZHOU
IPC分类号： C12N15/86 , A61K35/763 , A61K39/00 , A61P35/00 , C07K14/47 , C07K14/52 , C07K14/54 , C07K14/82 , C07K16/28
CPC分类号： C12N15/86 , A61K35/763 , A61K39/001106 , A61K39/001112 , A61K39/4611 , A61K39/4613 , A61K39/4631 , A61K39/464412 , A61P35/00 , C07K14/4748 , C07K14/521 , C07K14/5434 , C07K14/82 , C07K16/2818 , A61K2039/5256 , A61K2239/46 , A61K2239/57 , A61K2239/58 , C12N2710/16632 , C12N2710/16643
摘要： Disclosed is a genetically modified oncolytic herpes simplex virus (oHISV) encoding a truncated nonsignaling variant of at least one tumor associated/specific antigen, and at least one chemokine. The expression of the truncated nonsignaling variant and the chemokine is under the control of an immediate-early gene promoter of HSV, and the truncated nonsignaling variant is expressed and presented on a tumor cell surface as a biomarker upon replication of the oHSV in the tumor cell, and the chemokine is expressed and released to induce chemotaxis of an immune cell towards the tumor cell. The genetically modified oHSV can be used in combination with CAR-T, ADC, and/or BiTE therapies.
-
公开(公告)号：US12005121B2
公开(公告)日：2024-06-11
申请号：US17823492
申请日：2022-08-30
申请人： Yale University
发明人： Elias Quijano , Peter Glazer
IPC分类号： A61K47/54 , A61K39/00 , A61K47/68 , A61K48/00 , A61P35/00 , C07K14/47 , C07K14/52 , C07K16/44 , C12N15/11 , C12N15/113 , C12N15/87
CPC分类号： A61K47/549 , A61K47/6807 , A61K47/6851 , A61K48/0025 , A61K48/005 , A61P35/00 , C07K14/4747 , C07K14/52 , C07K16/44 , C12N15/111 , C12N15/113 , C12N15/1135 , C12N15/87 , A61K2039/505 , A61K48/00 , C07K2317/24 , C07K2317/31 , C07K2317/565 , C07K2317/622 , C07K2317/77 , C07K2319/33 , C12N2310/11 , C12N2310/14 , C12N2310/3181 , C12N2310/3513 , C12N2320/32
摘要： Compositions and methods of use thereof for delivering nucleic acid cargo into cells are provided. The compositions typically include (a) a 3E10 monoclonal antibody or an antigen binding, cell-penetrating fragment thereof; a monovalent, divalent, or multivalent single chain variable fragment (scFv); or a diabody; or humanized form or variant thereof, and (b) a nucleic acid cargo including, for example, a nucleic acid encoding a polypeptide, a functional nucleic acid, a nucleic acid encoding a functional nucleic acid, or a combination thereof. Elements (a) and (b) are typically non-covalently linked to form a complex.
-
公开(公告)号：US20240166758A1
公开(公告)日：2024-05-23
申请号：US18500706
申请日：2023-11-02
发明人： Stanley R. RIDDELL , Damian GREEN , Tyler HILL
IPC分类号： C07K16/28 , A61K9/00 , A61K31/192 , A61K31/216 , A61K31/417 , A61K31/4245 , A61K31/5513 , A61P35/00 , C07K14/475 , C07K14/52 , C07K16/40
CPC分类号： C07K16/2878 , A61K9/0053 , A61K31/192 , A61K31/216 , A61K31/417 , A61K31/4245 , A61K31/5513 , A61P35/00 , C07K14/475 , C07K14/52 , C07K16/2887 , C07K16/40 , A61K45/06
摘要： The present disclosure relates to methods for using BCMA-specific binding molecules (such as a BCMA-specific chimeric antigen receptor or antibody) in combination with γ-secretase inhibitors, which can be done concurrently or sequentially, to treat or prevent a B-cell related proliferative disease, such as a cancer or autoimmune disease, or the like. A BCMA-specific binding molecule in combination with γ-secretase inhibitor can be used in, for example, adoptive immunotherapy.
-
公开(公告)号：US20240165216A1
公开(公告)日：2024-05-23
申请号：US18551954
申请日：2022-03-21
申请人： CLIPSBNC CO., LTD.
发明人： Bum-Joon KIM , Dong Ho AHN , Hyein JEONG , Hyejun SEO , Jae Hee KIM
CPC分类号： A61K39/04 , A61K39/3955 , A61P35/00 , C07K14/52 , C07K14/5418 , C12N15/74 , A61K2039/505 , A61K2039/522 , A61K2039/523 , A61K2039/55522 , A61K2039/55527 , A61K2039/55594 , A61K2039/585
摘要： A recombinant Mycobacterium strain co-expressing MIF and IL-7, and a composition containing the strain as an active ingredient are disclosed. The strain and the composition are suitable for preventing or treating cancer. The strain induces a maximized anticancer immune response by stably expressing MIF and IL-7 through a mycobacteria-derived replicable plasmid, such as a pMyong2 shuttle vector. Accordingly, the strain and the composition may be usefully used as an efficient anticancer live vaccine composition that induces multiple cellular and humoral immune responses through single administration of the recombinant strain.
-
公开(公告)号：US11987615B2
公开(公告)日：2024-05-21
申请号：US17877612
申请日：2022-07-29
发明人： Yuan Guo , Baihong Liu , Yi Yang , Yuelei Shen
CPC分类号： C07K16/00 , C07K14/52 , C07K2317/24 , C07K2317/31 , C07K2317/524 , C07K2317/526 , C07K2317/622 , C07K2319/00
摘要： This disclosure relates to modified immunoglobulins.
-
10.发明授权公开(公告)号：US11965176B2
公开(公告)日：2024-04-23
申请号：US16980237
申请日：2019-03-13
发明人： Biliang Hu
IPC分类号： C07K14/525 , C07K14/475 , C07K14/52 , C07K14/53 , C07K14/54 , C07K14/705 , C07K16/18 , C07K16/24 , C12N5/078 , C12N5/0783 , C12N5/16 , C12N15/63
CPC分类号： C12N5/0634 , C07K14/475 , C07K14/52 , C07K14/525 , C07K14/53 , C07K14/54 , C07K14/705 , C07K16/18 , C07K16/248 , C12N5/16 , C12N15/63 , C07K2317/24 , C07K2317/622 , C12N2310/10 , C12N2310/11 , C12N2310/14 , C12N2310/20
摘要： A population of immune cells comprising modified immune cells with reduced inflammatory properties, wherein such modified immune cells may have reduced production of one or more inflammatory cytokines (e.g., interleukin 2) and/or express one or more antagonists of one or more inflammatory cytokines (e.g., interleukin 6). Also provided herein are methods of producing such immune cell populations comprising the modified immune cells and methods of using such in cell therapy (e.g., to treat cancer, infectious diseases or immune diseases).
-
-
-
-
-
-
-
-
-
搜索结果
3028 条记录 (耗时 0.036 秒)
